Exo Therapeutics, Inc.

Alan Saghatelian, PhD
Co-Founder

Alan Saghatelian, PhD, is a Professor and Frederik Paulsen Chair at the Salk Institute for Biological Studies and an adjunct Professor at the University of California, San Diego.

Dr. Saghatelian has published over 110 papers and six patents. Saghatelian was a recipient of the NIH New Innovator Award, a Searle Scholar Awardee, and a Sloan Foundation Fellow. Dr. Saghatelian’s research in chemical biology merges modern analytical techniques with biochemistry and chemical biology to identify genes that regulate fundamental biological pathways and can be targeted for the development of novel therapeutics.

Dr. Saghatelian graduated from the University of California, Los Angeles in 1997 with a degree in Chemistry. He carried out organic and organometallic chemistry research on the total synthesis of a marine natural product with anti-cancer activity in the lab of Professor Craig Merlic. He earned his PhD in Chemistry from The Scripps Research Institute in Chemistry working with Professor Reza Ghadiri. During graduate school, Dr. Saghatelian worked to develop new protein and peptide catalysts through chemical synthesis and protein engineering. Dr. Saghatelian performed his postdoctoral research with Professor Benjamin Cravatt at The Scripps Research Institute where he developed novel mass spectrometry approaches for global metabolite profiling. In 2006, Dr. Saghatelian started his independent career as an Assistant Professor in the Department of Chemistry and Chemical Biology at Harvard University, and in 2014, he moved to the Salk Institute for Biological Studies.